By Fineline Cube Merck & Co. (MSD, NYSE: MRK), Astellas Pharma (TYO: 4503), and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review to a supplemental Biologics License Application (sBLA) for the combination of Padcev® (enfortumab vedotin) and pembrolizumab—administered either intravenously or subcutaneously—for the perioperative (neoadjuvant and adjuvant) treatment of muscle-invasive bladder cancer (MIBC). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in Q3 2026.
Regulatory & Clinical Context
| Milestone | Status |
|---|---|
| Current Indication (US) | Approved for locally advanced or metastatic urothelial cancer (la/mUC) |
| November 2025 Approval | Neoadjuvant + adjuvant use in cisplatin-ineligible MIBC patients undergoing cystectomy |
| New sBLA Scope | Full perioperative regimen (pre- and post-surgery) in broader MIBC population, including cisplatin-eligible patients |
| Review Designation | Priority Review (6-month timeline vs. standard 10 months) |
| PDUFA Date | Expected Q3 2026 |
Drug Profiles
- Padcev (enfortumab vedotin): Antibody-drug conjugate (ADC) targeting Nectin-4, a protein highly expressed in urothelial cancers
- Pembrolizumab: Anti–PD-1 immune checkpoint inhibitor (available IV or SC)
- Combo Rationale: Synergistic mechanism—ADC delivers cytotoxic payload directly to tumor cells while pembrolizumab reactivates T-cell anti-tumor immunity
Muscle-invasive bladder cancer affects ~20,000 patients annually in the U.S., with radical cystectomy as standard care. However, >50% of patients relapse post-surgery, highlighting the need for effective systemic perioperative therapy.
Commercial & Strategic Implications
- Market Expansion: If approved, the combo could become the first systemic perioperative standard of care for MIBC, regardless of cisplatin eligibility
- Competitive Edge: No other regimen currently holds an FDA-approved perioperative indication in MIBC
- Revenue Upside: Analysts estimate peak annual sales of $2.5–3.0 billion across all urothelial cancer settings by 2030
- Global Alignment: U.S. approval would support similar filings in EU, Japan, and China, where la/mUC indications are already active
The companies are also evaluating subcutaneous pembrolizumab to improve patient convenience—a key differentiator in outpatient oncology.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory outcomes, commercial potential, and clinical development. Actual results may differ due to FDA decisions, competitive dynamics, and real-world adoption.-Fineline Info & Tech